SGLT2 Inhibitors May Shield Kidneys From Acute Injury Through Multiple Mechanisms

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) block glucose reabsorption in the proximal tubules of the kidney, causing glucosuria and modest blood sugar reduction. Since dapagliflozin's introduction in 2012, followed by canagliflozin and empagliflozin, these drugs have moved far beyond diabetes management. Large cardiovascular and kidney outcome trials — including EMPA-REG OUTCOME, CANVAS, CREDENCE, DAPA-CKD, and EMPA-KIDNEY — have demonstrated robust reductions in major adverse kidney events, heart failure hospitalizations, and cardiovascular death. This review from Brigham and Women's Hospital/Harvard Medical School synthesizes what is now known about SGLT2i effects specifically on acute kidney injury (AKI), integrating clinical trial data with mechanistic insights from animal models and biomarker studies.

The hemodynamic rationale for AKI protection centers on tubuloglomerular feedback (TGF). In diabetes, high glucose loads overwhelm SGLT2 and SGLT1 capacity in the proximal tubule, reducing luminal sodium delivery to the macula densa, which blunts TGF and drives glomerular hyperfiltration. SGLT2 inhibition restores normal sodium delivery to the macula densa, normalizing afferent arteriole tone and reducing intraglomerular pressure. This same mechanism that lowers GFR acutely — often misread as harm — is actually protective over time by reducing the kidney's susceptibility to hyperfiltration-driven injury. During AKI, this hemodynamic buffering may prevent further pressure-related tubular damage.

Metabolic mechanisms are equally important. The proximal tubule is highly dependent on oxidative phosphorylation and thus vulnerable to ischemia. SGLT2i reduce the tubule's metabolic workload by decreasing active sodium-glucose cotransport, lowering oxygen consumption. Additionally, these drugs appear to shift substrate utilization: animal studies show SGLT2i promote ketone body use and reduce reliance on free fatty acids in the tubular epithelium, a metabolic shift associated with improved mitochondrial efficiency and reduced reactive oxygen species generation. This is particularly relevant during ischemic or septic AKI when mitochondrial dysfunction is a central driver of injury.

At the cellular and molecular level, the review highlights SGLT2i effects on inflammation, autophagy, and cellular senescence. Preclinical data show reductions in NF-κB activation, pro-inflammatory cytokines, and NLRP3 inflammasome activity. SGLT2i also appear to activate AMPK and promote autophagy, pathways critical for clearing damaged organelles and proteins after injury. Emerging evidence implicates SGLT2i in reducing tubular cell senescence — a state of irreversible growth arrest that contributes to maladaptive repair after AKI and progression to CKD. KIM-1 (kidney injury molecule-1), a sensitive AKI biomarker, is expressed in senescent cells and in maladaptively repairing tubules, and SGLT2i have been associated with reductions in urinary KIM-1 levels in clinical studies.

Clinical evidence is robust but not uniform. Post-hoc analyses of major cardiovascular outcome trials and dedicated kidney trials consistently show 20–40% reductions in AKI events with SGLT2i versus placebo. Importantly, these benefits appear to extend beyond diabetic patients, with trials like EMPA-KIDNEY and DAPA-CKD enrolling patients with non-diabetic CKD and still demonstrating kidney protection. The authors acknowledge important caveats: most AKI analyses are secondary endpoints or post-hoc analyses, not primary pre-specified outcomes; definitions of AKI vary across trials; and confounding from concurrent medications such as diuretics and renin-angiotensin system blockers complicates interpretation. Nonetheless, the convergence of mechanistic plausibility and consistent clinical signals across diverse populations strengthens the case for a genuine AKI-protective effect of SGLT2 inhibitors.